Skip to Main Content
Contact Us
Category: Article
Purpose-Built for ADC Development Antibody-drug conjugates (ADCs) are transforming cancer care by combining precision antibody targeting with potent payloads Read Now Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, and Proven Strategies In “Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, and Proven Strategies,” Susan Albert, VP Read Now The Importance of Critical Thinking in a Successful Organization  Why human insight remains essential in the age of AI  In an era increasingly defined Read Now Optimizing Global Early-phase Oncology Trials Strategies for Success  The clinical trial landscape is constantly evolving, particularly in oncology early development, Read Now Journal of Clinical Studies thumbnail photo of a group of women speaking at a conference table. The Role of Company Culture in Functional Service Provider (FSP) Partnerships Pharmaceutical and clinical research sponsors (clients) have long outsourced clinical development work, utilizing both full-service Read Now Medical professional on the phone and at her computer. Traditional Site Networks Are Broken Building Real Site Relationships to Facilitate the Success of Early Phase Oncology Trials Oncology clinical Read Now Graphic with blues and purples with a white computer icon in the center surrounded by a circle. Ensuring Flexibility when Approaching CTIS When Catalyst Oncology implements the European Union Clinical Trial Regulation (EU CTR) across Sponsor studies Read Now Catalyst Flex Excels as an Adaptable, Comprehensive FSP The biopharmaceutical industry increasingly turns to Catalyst Flex for its unique approach to functional service Read Now Graphic of Benefits of Working with Catalyst Oncology versus a large generalist CRO with an image of two people bathed in sunshine. Benefits of Working with Catalyst Oncology versus a Large Generalist CRO Oncology drug development continues to increase in its complexity. Large contract research organizations (CROs) are Read Now Expanding Clinical Trial Diversity: A Catalyst Values Approach “Today, overall cancer clinical trial enrollment in the United States is 8% (6.3%‐7.0% at community Read Now
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.